nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Ethinyl Estradiol—osteoporosis	0.219	0.365	CbGbCtD
Eprosartan—ABCC2—Conjugated Estrogens—osteoporosis	0.161	0.268	CbGbCtD
Eprosartan—CYP2C9—Estropipate—osteoporosis	0.114	0.19	CbGbCtD
Eprosartan—CYP2C9—Cholecalciferol—osteoporosis	0.0589	0.098	CbGbCtD
Eprosartan—CYP2C9—Estradiol—osteoporosis	0.0475	0.079	CbGbCtD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00535	0.218	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—REN—osteoporosis	0.00283	0.115	CbGpPWpGaD
Eprosartan—Losartan—ACE—osteoporosis	0.00233	1	CrCbGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—ACE—osteoporosis	0.00176	0.0718	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TUBA1B—osteoporosis	0.00122	0.0499	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000855	0.0348	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—MGLL—osteoporosis	0.000548	0.0223	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—osteoporosis	0.000543	0.0221	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000491	0.02	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.00049	0.0199	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—PTH1R—osteoporosis	0.000348	0.0142	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CALCR—osteoporosis	0.000348	0.0142	CbGpPWpGaD
Eprosartan—Shock—Pamidronate—osteoporosis	0.00033	0.000886	CcSEcCtD
Eprosartan—Loss of consciousness—Zoledronate—osteoporosis	0.00033	0.000886	CcSEcCtD
Eprosartan—Pharyngitis—Estradiol—osteoporosis	0.00033	0.000885	CcSEcCtD
Eprosartan—Hypersensitivity—Estropipate—osteoporosis	0.000329	0.000883	CcSEcCtD
Eprosartan—Thrombocytopenia—Pamidronate—osteoporosis	0.000328	0.000881	CcSEcCtD
Eprosartan—Vomiting—Etidronic acid—osteoporosis	0.000328	0.000881	CcSEcCtD
Eprosartan—Cough—Zoledronate—osteoporosis	0.000327	0.000879	CcSEcCtD
Eprosartan—Oedema peripheral—Estradiol—osteoporosis	0.000327	0.000879	CcSEcCtD
Eprosartan—Tachycardia—Pamidronate—osteoporosis	0.000327	0.000879	CcSEcCtD
Eprosartan—Rash—Etidronic acid—osteoporosis	0.000325	0.000873	CcSEcCtD
Eprosartan—Dermatitis—Etidronic acid—osteoporosis	0.000325	0.000872	CcSEcCtD
Eprosartan—Vertigo—Conjugated Estrogens—osteoporosis	0.000325	0.000872	CcSEcCtD
Eprosartan—Hyperhidrosis—Pamidronate—osteoporosis	0.000324	0.00087	CcSEcCtD
Eprosartan—Syncope—Conjugated Estrogens—osteoporosis	0.000324	0.00087	CcSEcCtD
Eprosartan—Hypersensitivity—Alendronate—osteoporosis	0.000324	0.00087	CcSEcCtD
Eprosartan—Headache—Etidronic acid—osteoporosis	0.000323	0.000868	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000321	0.000863	CcSEcCtD
Eprosartan—Asthenia—Estropipate—osteoporosis	0.00032	0.00086	CcSEcCtD
Eprosartan—Visual impairment—Estradiol—osteoporosis	0.00032	0.00086	CcSEcCtD
Eprosartan—Anorexia—Pamidronate—osteoporosis	0.000319	0.000858	CcSEcCtD
Eprosartan—Myalgia—Zoledronate—osteoporosis	0.000319	0.000858	CcSEcCtD
Eprosartan—Arthralgia—Zoledronate—osteoporosis	0.000319	0.000858	CcSEcCtD
Eprosartan—Chest pain—Zoledronate—osteoporosis	0.000319	0.000858	CcSEcCtD
Eprosartan—Palpitations—Conjugated Estrogens—osteoporosis	0.000319	0.000857	CcSEcCtD
Eprosartan—Insomnia—Risedronate—osteoporosis	0.000319	0.000856	CcSEcCtD
Eprosartan—Anxiety—Zoledronate—osteoporosis	0.000318	0.000855	CcSEcCtD
Eprosartan—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000317	0.000853	CcSEcCtD
Eprosartan—Paraesthesia—Risedronate—osteoporosis	0.000317	0.00085	CcSEcCtD
Eprosartan—Pruritus—Estropipate—osteoporosis	0.000316	0.000848	CcSEcCtD
Eprosartan—Discomfort—Zoledronate—osteoporosis	0.000316	0.000847	CcSEcCtD
Eprosartan—Asthenia—Alendronate—osteoporosis	0.000315	0.000847	CcSEcCtD
Eprosartan—Hypersensitivity—Ibandronate—osteoporosis	0.000315	0.000847	CcSEcCtD
Eprosartan—Cough—Conjugated Estrogens—osteoporosis	0.000315	0.000847	CcSEcCtD
Eprosartan—Dyspnoea—Risedronate—osteoporosis	0.000314	0.000844	CcSEcCtD
Eprosartan—Hypotension—Pamidronate—osteoporosis	0.000313	0.000841	CcSEcCtD
Eprosartan—Dry mouth—Zoledronate—osteoporosis	0.000312	0.000839	CcSEcCtD
Eprosartan—Fatigue—Ethinyl Estradiol—osteoporosis	0.000312	0.000837	CcSEcCtD
Eprosartan—Pruritus—Alendronate—osteoporosis	0.000311	0.000835	CcSEcCtD
Eprosartan—Dyspepsia—Risedronate—osteoporosis	0.00031	0.000834	CcSEcCtD
Eprosartan—Tinnitus—Estradiol—osteoporosis	0.00031	0.000832	CcSEcCtD
Eprosartan—Constipation—Ethinyl Estradiol—osteoporosis	0.000309	0.000831	CcSEcCtD
Eprosartan—Hypersensitivity—Calcitriol—osteoporosis	0.000309	0.000829	CcSEcCtD
Eprosartan—Arthralgia—Conjugated Estrogens—osteoporosis	0.000308	0.000826	CcSEcCtD
Eprosartan—Myalgia—Conjugated Estrogens—osteoporosis	0.000308	0.000826	CcSEcCtD
Eprosartan—Chest pain—Conjugated Estrogens—osteoporosis	0.000308	0.000826	CcSEcCtD
Eprosartan—Asthenia—Ibandronate—osteoporosis	0.000307	0.000824	CcSEcCtD
Eprosartan—Anxiety—Conjugated Estrogens—osteoporosis	0.000306	0.000823	CcSEcCtD
Eprosartan—Nausea—Etidronic acid—osteoporosis	0.000306	0.000823	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000305	0.00082	CcSEcCtD
Eprosartan—Diarrhoea—Estropipate—osteoporosis	0.000305	0.00082	CcSEcCtD
Eprosartan—Fatigue—Risedronate—osteoporosis	0.000304	0.000816	CcSEcCtD
Eprosartan—Insomnia—Pamidronate—osteoporosis	0.000303	0.000814	CcSEcCtD
Eprosartan—Pruritus—Ibandronate—osteoporosis	0.000303	0.000813	CcSEcCtD
Eprosartan—Pain—Risedronate—osteoporosis	0.000302	0.00081	CcSEcCtD
Eprosartan—Constipation—Risedronate—osteoporosis	0.000302	0.00081	CcSEcCtD
Eprosartan—Shock—Zoledronate—osteoporosis	0.000301	0.000809	CcSEcCtD
Eprosartan—Paraesthesia—Pamidronate—osteoporosis	0.000301	0.000808	CcSEcCtD
Eprosartan—Diarrhoea—Alendronate—osteoporosis	0.000301	0.000807	CcSEcCtD
Eprosartan—Asthenia—Calcitriol—osteoporosis	0.0003	0.000807	CcSEcCtD
Eprosartan—Thrombocytopenia—Zoledronate—osteoporosis	0.0003	0.000805	CcSEcCtD
Eprosartan—Dyspnoea—Pamidronate—osteoporosis	0.000299	0.000803	CcSEcCtD
Eprosartan—Tachycardia—Zoledronate—osteoporosis	0.000299	0.000803	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000298	0.0121	CbGpPWpGaD
Eprosartan—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000298	0.0008	CcSEcCtD
Eprosartan—Chills—Estradiol—osteoporosis	0.000298	0.0008	CcSEcCtD
Eprosartan—Somnolence—Pamidronate—osteoporosis	0.000298	0.0008	CcSEcCtD
Eprosartan—Pruritus—Calcitriol—osteoporosis	0.000296	0.000796	CcSEcCtD
Eprosartan—Hyperhidrosis—Zoledronate—osteoporosis	0.000296	0.000795	CcSEcCtD
Eprosartan—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000296	0.000794	CcSEcCtD
Eprosartan—Diarrhoea—Raloxifene—osteoporosis	0.000296	0.000794	CcSEcCtD
Eprosartan—Dyspepsia—Pamidronate—osteoporosis	0.000295	0.000792	CcSEcCtD
Eprosartan—Dizziness—Estropipate—osteoporosis	0.000295	0.000792	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000294	0.012	CbGpPWpGaD
Eprosartan—Diarrhoea—Ibandronate—osteoporosis	0.000293	0.000786	CcSEcCtD
Eprosartan—Anorexia—Zoledronate—osteoporosis	0.000292	0.000784	CcSEcCtD
Eprosartan—Decreased appetite—Pamidronate—osteoporosis	0.000291	0.000783	CcSEcCtD
Eprosartan—Dizziness—Alendronate—osteoporosis	0.000291	0.00078	CcSEcCtD
Eprosartan—Shock—Conjugated Estrogens—osteoporosis	0.00029	0.000779	CcSEcCtD
Eprosartan—Fatigue—Pamidronate—osteoporosis	0.000289	0.000776	CcSEcCtD
Eprosartan—Gastrointestinal pain—Risedronate—osteoporosis	0.000288	0.000774	CcSEcCtD
Eprosartan—Tachycardia—Conjugated Estrogens—osteoporosis	0.000288	0.000773	CcSEcCtD
Eprosartan—Urticaria—Ethinyl Estradiol—osteoporosis	0.000287	0.000772	CcSEcCtD
Eprosartan—Constipation—Pamidronate—osteoporosis	0.000287	0.00077	CcSEcCtD
Eprosartan—Pain—Pamidronate—osteoporosis	0.000287	0.00077	CcSEcCtD
Eprosartan—Diarrhoea—Calcitriol—osteoporosis	0.000287	0.00077	CcSEcCtD
Eprosartan—Hypotension—Zoledronate—osteoporosis	0.000286	0.000768	CcSEcCtD
Eprosartan—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000286	0.000768	CcSEcCtD
Eprosartan—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000286	0.000768	CcSEcCtD
Eprosartan—Dizziness—Raloxifene—osteoporosis	0.000286	0.000768	CcSEcCtD
Eprosartan—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000285	0.000765	CcSEcCtD
Eprosartan—Flatulence—Estradiol—osteoporosis	0.000285	0.000765	CcSEcCtD
Eprosartan—Tension—Estradiol—osteoporosis	0.000284	0.000762	CcSEcCtD
Eprosartan—Vomiting—Estropipate—osteoporosis	0.000284	0.000762	CcSEcCtD
Eprosartan—Dizziness—Ibandronate—osteoporosis	0.000283	0.00076	CcSEcCtD
Eprosartan—Rash—Estropipate—osteoporosis	0.000281	0.000756	CcSEcCtD
Eprosartan—Dermatitis—Estropipate—osteoporosis	0.000281	0.000755	CcSEcCtD
Eprosartan—Anorexia—Conjugated Estrogens—osteoporosis	0.000281	0.000755	CcSEcCtD
Eprosartan—Nervousness—Estradiol—osteoporosis	0.000281	0.000754	CcSEcCtD
Eprosartan—Urticaria—Risedronate—osteoporosis	0.00028	0.000752	CcSEcCtD
Eprosartan—Back pain—Estradiol—osteoporosis	0.00028	0.000751	CcSEcCtD
Eprosartan—Headache—Estropipate—osteoporosis	0.000279	0.000751	CcSEcCtD
Eprosartan—Vomiting—Alendronate—osteoporosis	0.000279	0.00075	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000279	0.000749	CcSEcCtD
Eprosartan—Body temperature increased—Risedronate—osteoporosis	0.000279	0.000749	CcSEcCtD
Eprosartan—Abdominal pain—Risedronate—osteoporosis	0.000279	0.000749	CcSEcCtD
Eprosartan—Muscle spasms—Estradiol—osteoporosis	0.000278	0.000746	CcSEcCtD
Eprosartan—Rash—Alendronate—osteoporosis	0.000277	0.000744	CcSEcCtD
Eprosartan—Insomnia—Zoledronate—osteoporosis	0.000277	0.000744	CcSEcCtD
Eprosartan—Dermatitis—Alendronate—osteoporosis	0.000277	0.000743	CcSEcCtD
Eprosartan—Feeling abnormal—Pamidronate—osteoporosis	0.000276	0.000742	CcSEcCtD
Eprosartan—Hypotension—Conjugated Estrogens—osteoporosis	0.000275	0.00074	CcSEcCtD
Eprosartan—Headache—Alendronate—osteoporosis	0.000275	0.000739	CcSEcCtD
Eprosartan—Paraesthesia—Zoledronate—osteoporosis	0.000275	0.000738	CcSEcCtD
Eprosartan—Vomiting—Raloxifene—osteoporosis	0.000275	0.000738	CcSEcCtD
Eprosartan—Gastrointestinal pain—Pamidronate—osteoporosis	0.000274	0.000736	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000273	0.0111	CbGpPWpGaD
Eprosartan—Dyspnoea—Zoledronate—osteoporosis	0.000273	0.000733	CcSEcCtD
Eprosartan—Rash—Raloxifene—osteoporosis	0.000272	0.000732	CcSEcCtD
Eprosartan—Dermatitis—Raloxifene—osteoporosis	0.000272	0.000731	CcSEcCtD
Eprosartan—Somnolence—Zoledronate—osteoporosis	0.000272	0.000731	CcSEcCtD
Eprosartan—Vomiting—Ibandronate—osteoporosis	0.000272	0.000731	CcSEcCtD
Eprosartan—Tremor—Estradiol—osteoporosis	0.000271	0.000727	CcSEcCtD
Eprosartan—Headache—Raloxifene—osteoporosis	0.000271	0.000727	CcSEcCtD
Eprosartan—Rash—Ibandronate—osteoporosis	0.00027	0.000724	CcSEcCtD
Eprosartan—Dermatitis—Ibandronate—osteoporosis	0.000269	0.000724	CcSEcCtD
Eprosartan—Dyspepsia—Zoledronate—osteoporosis	0.000269	0.000724	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000269	0.000721	CcSEcCtD
Eprosartan—Ill-defined disorder—Estradiol—osteoporosis	0.000268	0.00072	CcSEcCtD
Eprosartan—Headache—Ibandronate—osteoporosis	0.000268	0.00072	CcSEcCtD
Eprosartan—Insomnia—Conjugated Estrogens—osteoporosis	0.000267	0.000716	CcSEcCtD
Eprosartan—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000266	0.000716	CcSEcCtD
Eprosartan—Vomiting—Calcitriol—osteoporosis	0.000266	0.000715	CcSEcCtD
Eprosartan—Decreased appetite—Zoledronate—osteoporosis	0.000266	0.000715	CcSEcCtD
Eprosartan—Nausea—Estropipate—osteoporosis	0.000265	0.000712	CcSEcCtD
Eprosartan—Abdominal pain—Pamidronate—osteoporosis	0.000265	0.000712	CcSEcCtD
Eprosartan—Body temperature increased—Pamidronate—osteoporosis	0.000265	0.000712	CcSEcCtD
Eprosartan—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000265	0.000711	CcSEcCtD
Eprosartan—Angioedema—Estradiol—osteoporosis	0.000264	0.000709	CcSEcCtD
Eprosartan—Rash—Calcitriol—osteoporosis	0.000264	0.000709	CcSEcCtD
Eprosartan—Fatigue—Zoledronate—osteoporosis	0.000264	0.000709	CcSEcCtD
Eprosartan—Dermatitis—Calcitriol—osteoporosis	0.000264	0.000709	CcSEcCtD
Eprosartan—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000263	0.000706	CcSEcCtD
Eprosartan—Headache—Calcitriol—osteoporosis	0.000262	0.000705	CcSEcCtD
Eprosartan—Somnolence—Conjugated Estrogens—osteoporosis	0.000262	0.000704	CcSEcCtD
Eprosartan—Constipation—Zoledronate—osteoporosis	0.000262	0.000703	CcSEcCtD
Eprosartan—Pain—Zoledronate—osteoporosis	0.000262	0.000703	CcSEcCtD
Eprosartan—Nausea—Alendronate—osteoporosis	0.000261	0.000701	CcSEcCtD
Eprosartan—Malaise—Estradiol—osteoporosis	0.000261	0.0007	CcSEcCtD
Eprosartan—Hypersensitivity—Risedronate—osteoporosis	0.00026	0.000698	CcSEcCtD
Eprosartan—Vertigo—Estradiol—osteoporosis	0.00026	0.000698	CcSEcCtD
Eprosartan—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000259	0.000697	CcSEcCtD
Eprosartan—Asthenia—Ethinyl Estradiol—osteoporosis	0.000259	0.000697	CcSEcCtD
Eprosartan—Syncope—Estradiol—osteoporosis	0.000259	0.000696	CcSEcCtD
Eprosartan—Nausea—Raloxifene—osteoporosis	0.000257	0.000689	CcSEcCtD
Eprosartan—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000256	0.000688	CcSEcCtD
Eprosartan—Pruritus—Ethinyl Estradiol—osteoporosis	0.000256	0.000687	CcSEcCtD
Eprosartan—Palpitations—Estradiol—osteoporosis	0.000255	0.000686	CcSEcCtD
Eprosartan—Fatigue—Conjugated Estrogens—osteoporosis	0.000254	0.000683	CcSEcCtD
Eprosartan—Nausea—Ibandronate—osteoporosis	0.000254	0.000683	CcSEcCtD
Eprosartan—Loss of consciousness—Estradiol—osteoporosis	0.000254	0.000682	CcSEcCtD
Eprosartan—Asthenia—Risedronate—osteoporosis	0.000253	0.000679	CcSEcCtD
Eprosartan—Feeling abnormal—Zoledronate—osteoporosis	0.000252	0.000678	CcSEcCtD
Eprosartan—Cough—Estradiol—osteoporosis	0.000252	0.000678	CcSEcCtD
Eprosartan—Constipation—Conjugated Estrogens—osteoporosis	0.000252	0.000677	CcSEcCtD
Eprosartan—Pain—Conjugated Estrogens—osteoporosis	0.000252	0.000677	CcSEcCtD
Eprosartan—Gastrointestinal pain—Zoledronate—osteoporosis	0.00025	0.000672	CcSEcCtD
Eprosartan—Pruritus—Risedronate—osteoporosis	0.000249	0.00067	CcSEcCtD
Eprosartan—Nausea—Calcitriol—osteoporosis	0.000249	0.000668	CcSEcCtD
Eprosartan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000247	0.000665	CcSEcCtD
Eprosartan—Hypersensitivity—Pamidronate—osteoporosis	0.000247	0.000663	CcSEcCtD
Eprosartan—Arthralgia—Estradiol—osteoporosis	0.000246	0.000661	CcSEcCtD
Eprosartan—Myalgia—Estradiol—osteoporosis	0.000246	0.000661	CcSEcCtD
Eprosartan—Chest pain—Estradiol—osteoporosis	0.000246	0.000661	CcSEcCtD
Eprosartan—Anxiety—Estradiol—osteoporosis	0.000245	0.000659	CcSEcCtD
Eprosartan—Urticaria—Zoledronate—osteoporosis	0.000243	0.000653	CcSEcCtD
Eprosartan—Discomfort—Estradiol—osteoporosis	0.000243	0.000653	CcSEcCtD
Eprosartan—Body temperature increased—Zoledronate—osteoporosis	0.000242	0.00065	CcSEcCtD
Eprosartan—Abdominal pain—Zoledronate—osteoporosis	0.000242	0.00065	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000242	0.00984	CbGpPWpGaD
Eprosartan—Diarrhoea—Risedronate—osteoporosis	0.000241	0.000648	CcSEcCtD
Eprosartan—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000241	0.000647	CcSEcCtD
Eprosartan—Dry mouth—Estradiol—osteoporosis	0.000241	0.000646	CcSEcCtD
Eprosartan—Asthenia—Pamidronate—osteoporosis	0.00024	0.000646	CcSEcCtD
Eprosartan—Dizziness—Ethinyl Estradiol—osteoporosis	0.000239	0.000642	CcSEcCtD
Eprosartan—Pruritus—Pamidronate—osteoporosis	0.000237	0.000637	CcSEcCtD
Eprosartan—Urticaria—Conjugated Estrogens—osteoporosis	0.000234	0.000629	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000234	0.00952	CbGpPWpGaD
Eprosartan—Dizziness—Risedronate—osteoporosis	0.000233	0.000626	CcSEcCtD
Eprosartan—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000233	0.000626	CcSEcCtD
Eprosartan—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000233	0.000626	CcSEcCtD
Eprosartan—Shock—Estradiol—osteoporosis	0.000232	0.000623	CcSEcCtD
Eprosartan—Tachycardia—Estradiol—osteoporosis	0.00023	0.000618	CcSEcCtD
Eprosartan—Vomiting—Ethinyl Estradiol—osteoporosis	0.00023	0.000618	CcSEcCtD
Eprosartan—Diarrhoea—Pamidronate—osteoporosis	0.000229	0.000616	CcSEcCtD
Eprosartan—Hyperhidrosis—Estradiol—osteoporosis	0.000228	0.000613	CcSEcCtD
Eprosartan—Rash—Ethinyl Estradiol—osteoporosis	0.000228	0.000612	CcSEcCtD
Eprosartan—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000228	0.000612	CcSEcCtD
Eprosartan—Headache—Ethinyl Estradiol—osteoporosis	0.000227	0.000608	CcSEcCtD
Eprosartan—Hypersensitivity—Zoledronate—osteoporosis	0.000226	0.000606	CcSEcCtD
Eprosartan—Vomiting—Risedronate—osteoporosis	0.000224	0.000602	CcSEcCtD
Eprosartan—Rash—Risedronate—osteoporosis	0.000222	0.000597	CcSEcCtD
Eprosartan—Dermatitis—Risedronate—osteoporosis	0.000222	0.000597	CcSEcCtD
Eprosartan—Dizziness—Pamidronate—osteoporosis	0.000222	0.000595	CcSEcCtD
Eprosartan—Headache—Risedronate—osteoporosis	0.000221	0.000593	CcSEcCtD
Eprosartan—Asthenia—Zoledronate—osteoporosis	0.00022	0.00059	CcSEcCtD
Eprosartan—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000217	0.000583	CcSEcCtD
Eprosartan—Pruritus—Zoledronate—osteoporosis	0.000217	0.000582	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000216	0.00878	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000215	0.000577	CcSEcCtD
Eprosartan—Nausea—Ethinyl Estradiol—osteoporosis	0.000215	0.000577	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—osteoporosis	0.000214	0.00871	CbGpPWpGaD
Eprosartan—Insomnia—Estradiol—osteoporosis	0.000213	0.000573	CcSEcCtD
Eprosartan—Vomiting—Pamidronate—osteoporosis	0.000213	0.000572	CcSEcCtD
Eprosartan—Paraesthesia—Estradiol—osteoporosis	0.000212	0.000569	CcSEcCtD
Eprosartan—Asthenia—Conjugated Estrogens—osteoporosis	0.000212	0.000568	CcSEcCtD
Eprosartan—Rash—Pamidronate—osteoporosis	0.000211	0.000568	CcSEcCtD
Eprosartan—Dermatitis—Pamidronate—osteoporosis	0.000211	0.000567	CcSEcCtD
Eprosartan—Dyspnoea—Estradiol—osteoporosis	0.00021	0.000565	CcSEcCtD
Eprosartan—Headache—Pamidronate—osteoporosis	0.00021	0.000564	CcSEcCtD
Eprosartan—Somnolence—Estradiol—osteoporosis	0.00021	0.000563	CcSEcCtD
Eprosartan—Diarrhoea—Zoledronate—osteoporosis	0.000209	0.000563	CcSEcCtD
Eprosartan—Nausea—Risedronate—osteoporosis	0.000209	0.000562	CcSEcCtD
Eprosartan—Pruritus—Conjugated Estrogens—osteoporosis	0.000209	0.00056	CcSEcCtD
Eprosartan—Dyspepsia—Estradiol—osteoporosis	0.000208	0.000558	CcSEcCtD
Eprosartan—Decreased appetite—Estradiol—osteoporosis	0.000205	0.000551	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL1B—osteoporosis	0.000204	0.00832	CbGpPWpGaD
Eprosartan—Fatigue—Estradiol—osteoporosis	0.000203	0.000546	CcSEcCtD
Eprosartan—Dizziness—Zoledronate—osteoporosis	0.000202	0.000544	CcSEcCtD
Eprosartan—Pain—Estradiol—osteoporosis	0.000202	0.000542	CcSEcCtD
Eprosartan—Constipation—Estradiol—osteoporosis	0.000202	0.000542	CcSEcCtD
Eprosartan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000202	0.000542	CcSEcCtD
Eprosartan—Nausea—Pamidronate—osteoporosis	0.000199	0.000535	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PTH1R—osteoporosis	0.000197	0.008	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CALCR—osteoporosis	0.000197	0.008	CbGpPWpGaD
Eprosartan—Dizziness—Conjugated Estrogens—osteoporosis	0.000195	0.000524	CcSEcCtD
Eprosartan—Vomiting—Zoledronate—osteoporosis	0.000195	0.000523	CcSEcCtD
Eprosartan—Feeling abnormal—Estradiol—osteoporosis	0.000194	0.000522	CcSEcCtD
Eprosartan—Rash—Zoledronate—osteoporosis	0.000193	0.000518	CcSEcCtD
Eprosartan—Gastrointestinal pain—Estradiol—osteoporosis	0.000193	0.000518	CcSEcCtD
Eprosartan—Dermatitis—Zoledronate—osteoporosis	0.000193	0.000518	CcSEcCtD
Eprosartan—Headache—Zoledronate—osteoporosis	0.000192	0.000515	CcSEcCtD
Eprosartan—Vomiting—Conjugated Estrogens—osteoporosis	0.000187	0.000503	CcSEcCtD
Eprosartan—Urticaria—Estradiol—osteoporosis	0.000187	0.000503	CcSEcCtD
Eprosartan—Body temperature increased—Estradiol—osteoporosis	0.000187	0.000501	CcSEcCtD
Eprosartan—Abdominal pain—Estradiol—osteoporosis	0.000187	0.000501	CcSEcCtD
Eprosartan—Rash—Conjugated Estrogens—osteoporosis	0.000186	0.000499	CcSEcCtD
Eprosartan—Dermatitis—Conjugated Estrogens—osteoporosis	0.000186	0.000499	CcSEcCtD
Eprosartan—Headache—Conjugated Estrogens—osteoporosis	0.000185	0.000496	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—PTH—osteoporosis	0.000183	0.00744	CbGpPWpGaD
Eprosartan—Nausea—Zoledronate—osteoporosis	0.000182	0.000488	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PTH1R—osteoporosis	0.000179	0.00727	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CALCR—osteoporosis	0.000179	0.00727	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CNR2—osteoporosis	0.000178	0.00725	CbGpPWpGaD
Eprosartan—Nausea—Conjugated Estrogens—osteoporosis	0.000175	0.00047	CcSEcCtD
Eprosartan—Hypersensitivity—Estradiol—osteoporosis	0.000174	0.000467	CcSEcCtD
Eprosartan—Asthenia—Estradiol—osteoporosis	0.000169	0.000455	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—WNT1—osteoporosis	0.000167	0.00682	CbGpPWpGaD
Eprosartan—Pruritus—Estradiol—osteoporosis	0.000167	0.000448	CcSEcCtD
Eprosartan—Diarrhoea—Estradiol—osteoporosis	0.000161	0.000434	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—TGFB1—osteoporosis	0.000159	0.00647	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000157	0.00638	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—MGLL—osteoporosis	0.000156	0.00636	CbGpPWpGaD
Eprosartan—Dizziness—Estradiol—osteoporosis	0.000156	0.000419	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000155	0.00629	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—PTHLH—osteoporosis	0.000151	0.00616	CbGpPWpGaD
Eprosartan—Vomiting—Estradiol—osteoporosis	0.00015	0.000403	CcSEcCtD
Eprosartan—Rash—Estradiol—osteoporosis	0.000149	0.0004	CcSEcCtD
Eprosartan—Dermatitis—Estradiol—osteoporosis	0.000149	0.000399	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—TNF—osteoporosis	0.000148	0.00604	CbGpPWpGaD
Eprosartan—Headache—Estradiol—osteoporosis	0.000148	0.000397	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000148	0.00601	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—AGER—osteoporosis	0.000144	0.00584	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MGLL—osteoporosis	0.000142	0.00577	CbGpPWpGaD
Eprosartan—Nausea—Estradiol—osteoporosis	0.00014	0.000376	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—POMC—osteoporosis	0.000137	0.00556	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CALCA—osteoporosis	0.000133	0.00543	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000128	0.00523	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000127	0.00517	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000127	0.00516	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000122	0.00497	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000121	0.00491	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SOST—osteoporosis	0.000117	0.00475	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTH1R—osteoporosis	0.000105	0.00429	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CALCR—osteoporosis	0.000105	0.00429	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PTH—osteoporosis	0.000103	0.0042	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CNR2—osteoporosis	0.000101	0.0041	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	9.41e-05	0.00383	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTH—osteoporosis	9.38e-05	0.00382	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	9.16e-05	0.00373	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CNR2—osteoporosis	9.14e-05	0.00372	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—WNT1—osteoporosis	8.59e-05	0.0035	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	8.59e-05	0.00349	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PTHLH—osteoporosis	8.56e-05	0.00348	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MGLL—osteoporosis	8.38e-05	0.00341	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LRP5—osteoporosis	8.18e-05	0.00333	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	8.14e-05	0.00331	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LRP6—osteoporosis	7.82e-05	0.00318	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTHLH—osteoporosis	7.77e-05	0.00316	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.63e-05	0.00311	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CALCA—osteoporosis	7.53e-05	0.00307	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—POMC—osteoporosis	6.98e-05	0.00284	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CALCA—osteoporosis	6.84e-05	0.00278	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	6.75e-05	0.00275	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	6.65e-05	0.00271	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TLN1—osteoporosis	6.6e-05	0.00269	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	6.33e-05	0.00258	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	6.17e-05	0.00251	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—osteoporosis	6.07e-05	0.00247	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—P4HB—osteoporosis	5.7e-05	0.00232	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTH—osteoporosis	5.54e-05	0.00226	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAP1A—osteoporosis	5.44e-05	0.00222	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CNR2—osteoporosis	5.4e-05	0.0022	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	5.38e-05	0.00219	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ADCY5—osteoporosis	5.36e-05	0.00218	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFATC1—osteoporosis	5.31e-05	0.00216	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—DKK1—osteoporosis	5.27e-05	0.00214	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—WNT1—osteoporosis	5.08e-05	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGA—osteoporosis	4.94e-05	0.00201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.93e-05	0.00201	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ADCY5—osteoporosis	4.87e-05	0.00198	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTHLH—osteoporosis	4.59e-05	0.00187	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BMP2—osteoporosis	4.59e-05	0.00187	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.58e-05	0.00187	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGB—osteoporosis	4.49e-05	0.00183	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSMA2—osteoporosis	4.34e-05	0.00177	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSMA5—osteoporosis	4.34e-05	0.00177	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.19e-05	0.00171	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—POMC—osteoporosis	4.05e-05	0.00165	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CALCA—osteoporosis	4.04e-05	0.00165	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—POMC—osteoporosis	3.94e-05	0.0016	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FDPS—osteoporosis	3.82e-05	0.00156	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PKM—osteoporosis	3.82e-05	0.00156	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KL—osteoporosis	3.67e-05	0.00149	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPD2—osteoporosis	3.62e-05	0.00148	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PGLS—osteoporosis	3.62e-05	0.00148	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—POMC—osteoporosis	3.58e-05	0.00146	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6R—osteoporosis	3.49e-05	0.00142	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PNP—osteoporosis	3.32e-05	0.00135	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ATIC—osteoporosis	3.32e-05	0.00135	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADCY5—osteoporosis	2.87e-05	0.00117	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—OXCT1—osteoporosis	2.82e-05	0.00115	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA2—osteoporosis	2.82e-05	0.00115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SPP1—osteoporosis	2.78e-05	0.00113	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MGLL—osteoporosis	2.75e-05	0.00112	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.59e-05	0.00105	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IRS2—osteoporosis	2.52e-05	0.00102	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—osteoporosis	2.46e-05	0.001	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—osteoporosis	2.35e-05	0.000957	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—IDH2—osteoporosis	2.34e-05	0.000951	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP27A1—osteoporosis	2.2e-05	0.000894	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IRS1—osteoporosis	2.2e-05	0.000894	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACP5—osteoporosis	2.14e-05	0.00087	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—POMC—osteoporosis	2.11e-05	0.000861	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.11e-05	0.000859	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6R—osteoporosis	2.06e-05	0.00084	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1—osteoporosis	2.03e-05	0.000828	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TPI1—osteoporosis	1.99e-05	0.000808	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—P4HB—osteoporosis	1.87e-05	0.00076	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GAPDH—osteoporosis	1.83e-05	0.000746	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RAP1A—osteoporosis	1.79e-05	0.000727	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.56e-05	0.000634	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—osteoporosis	1.56e-05	0.000633	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO1—osteoporosis	1.44e-05	0.000587	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSMA5—osteoporosis	1.42e-05	0.000579	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSMA2—osteoporosis	1.42e-05	0.000579	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—osteoporosis	1.22e-05	0.000498	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—osteoporosis	1.22e-05	0.000496	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.15e-05	0.00047	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADCY5—osteoporosis	9.43e-06	0.000384	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX1—osteoporosis	9.39e-06	0.000382	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—osteoporosis	9.19e-06	0.000374	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—osteoporosis	8.67e-06	0.000353	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—POMC—osteoporosis	6.93e-06	0.000282	CbGpPWpGaD
